The Latest in Melanoma

The Journal of Community and Supportive Oncology

Metastatic eccrine carcinoma with stomach and pericardial involvement

December 15, 2017

Oncology Practice

First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance

December 2, 2017

Oncology Practice

Breakthrough cancer gene assay approved, CMS proposes coverage

December 1, 2017

Oncology Practice

Gut bacteria influenced response to checkpoint inhibitors

November 14, 2017

Oncology Practice

Neoantigen profiling predicts response to immunotherapy

November 8, 2017

Oncology Practice

T-VEC improves melanoma response without toxicity increase

October 20, 2017

Melanoma

Oncology Practice

Liquid biopsy predicts checkpoint inhibitor response

October 2, 2017

Oncology Practice

Lithium may reduce melanoma risk

September 28, 2017

Melanoma

Oncology Practice

Mitotic rate not tied to SLN biopsy results in thin melanomas

September 18, 2017

Melanoma

Oncology Practice

Adding T-vec might help surmount PD-1 resistance in melanoma

September 14, 2017

Oncology Practice

COMBI-AD: Adjuvant combo halves relapses in BRAF V600-mutated melanoma

September 12, 2017

Melanoma

Oncology Practice

Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanoma

September 11, 2017

The Journal of Community and Supportive Oncology

Bone remodeling associated with CTLA-4 inhibition: an unreported side effect

September 8, 2017

The Journal of Community and Supportive Oncology

Intramedullary spinal cord and leptomeningeal metastases presenting as cauda equina syndrome in a patient with melanoma

September 7, 2017

Oncology Practice

Pembrolizumab, nivolumab linked to 3% rate of neurologic events

September 5, 2017